StreetInsider.com News Articles

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Wed, 04 Mar 2026 16:20:00 -0500

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK
SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026
Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026
SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

JERSEY CITY, N.J., March

Form 10-K SCYNEXIS INC For: Dec 31

Wed, 04 Mar 2026 16:02:00 -0500

si-local-file:///var/storage/secattach/20260304/26110836.html

Form 10-K SCYNEXIS INC For: Dec 31

Wed, 04 Mar 2026 16:02:00 -0500

si-local-file:///var/storage/secattach/20260304/26110836.html

SCYNEXIS begins Phase 1 trial of intravenous SCY-247 antifungal therapy

Thu, 26 Feb 2026 08:23:43 -0500

SCYNEXIS Inc. (NASDAQ: SCYX) announced that the first participants have been dosed in a Phase 1 single ascending dose and multiple ascending dose trial evaluating the intravenous formulation of SCY-247, its second-generation triterpenoid antifungal therapy.

The trial is evaluating SCY-247 as a treatment for invasive candidiasis and as a prophylaxis therapy for invasive fungal disease. Results from the trial are expected in 2026, according to the company's statement.

SCY-247 received Qualified Infectious Disease Product and Fast Track designations from the U.S. Food and Drug Administration in January 2026. The designations were granted based on the drug's potential role in addressing antifungal resistance.

"An

SCYNEXIS begins Phase 1 trial of intravenous SCY-247 antifungal therapy

Thu, 26 Feb 2026 08:23:43 -0500

"An

SCYNEXIS begins Phase 1 trial of intravenous SCY-247 antifungal therapy

Thu, 26 Feb 2026 08:23:43 -0500

"An